Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368636 | 0.94 | ADRB3 (0.55) | ADRB3ADRB2 | |
| SCHEMBL3365509 | 0.92 | ADRB3 (0.60) | ADRB3 | |
| SCHEMBL3366354 | 0.92 | ADRB3 (0.53) | ADRB3ADRB2 | |
| SCHEMBL3368941 | 0.90 | ADRB3 (0.55) | ADRB3ADRB2 | |
| SCHEMBL3367699 | 0.88 | ADRB3 (0.50) | ADRB3ADRB2 | |
| SCHEMBL4984614 | 0.86 | ADRB3 (0.50) | ADRB3ADRB2 | |
| SCHEMBL4013128 | 0.85 | ADRB2 (0.52) | ADRB3ADRB2 | |
| SCHEMBL13181772 | 0.85 | ADRB2 (0.38) | ADRB3ADRB2 | |
| SCHEMBL3367731 | 0.84 | ADRB2 (0.52) | ADRB3ADRB2 | |
| SCHEMBL3366345 | 0.83 | ADRB3 (0.58) | ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720546-B1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| EP-1720546-A1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005077361-A1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | ADRB2, ADRA2A, ADRA2C | ADRB3 6/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.